Skip to main content
IMMUTEP LIMITED logo

IMMUTEP LIMITED — Investor Relations & Filings

Ticker · IMM ISIN · AU000000IMM6 LEI · 529900OL6C5CY5P8BH38 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,780 across all filing types
Latest filing 2024-10-20 Major Shareholding Noti…
Country AU Australia
Listing ASX IMM

About IMMUTEP LIMITED

https://www.immutep.com

Immutep Limited focuses on the development of novel immunotherapy treatments for cancer and autoimmune diseases, specifically targeting the Lymphocyte Activation Gene-3 (LAG-3) pathway. The company's lead therapeutic candidate is eftilagimod alpha (efti), a first-in-class soluble LAG-3 protein and MHC class II agonist. Efti functions by activating antigen-presenting cells, which in turn triggers a robust T cell response against tumors. It is currently being evaluated in clinical trials for multiple solid tumor indications, including non-small cell lung cancer and head and neck squamous cell carcinoma, frequently in combination with other anti-cancer agents. The pipeline also includes IMP761, an agonist antibody designed to suppress overactive immune responses in autoimmune conditions. The company's technology utilizes the LAG-3 protein's role in immune regulation to create targeted therapeutic interventions.

Recent filings

Filing Released Lang Actions
Ceasing to be a substantial holder 13 pages 612.9KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 filed under the Corporations Act 2001 Section 671B, titled 'Notice of ceasing to be a substantial holder.' It details changes in relevant interests of a substantial shareholder (JPMorgan Chase & Co. and affiliates) in the voting securities of IMMUTEP LTD. The form includes transaction dates, nature of changes, and securities affected, along with appendices describing securities lending agreements and voting rights restrictions. This type of filing is a notification of changes in significant share ownership levels, specifically ceasing to be a substantial holder, which aligns with the category 'Major Shareholding Notification' (MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory notice about shareholding changes.
2024-10-20 English
Change in substantial holding 6 pages 334.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of Change of Interests of Substantial Holder filed under the Corporations Act 2001. It details changes in voting power and relevant interests of The Bank of New York Mellon Corporation and its group entities in Immutep Limited. The document includes dates of changes, nature of changes, and relevant securities holdings. It is a regulatory filing notifying the market of changes in substantial shareholdings, not a financial report, earnings release, or management report. It does not contain financial statements or management discussion but is a formal disclosure of shareholding changes as required by law. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is sufficient and contains detailed information about shareholding changes, confirming it is not a brief announcement or certification but a substantive notification.
2024-10-17 English
IMP761 Progresses to Dose Escalation Portion of Ph1 Trial 2 pages 243.9KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the progress of a clinical trial (Phase I study) for a drug candidate IMP761 by Immutep Limited. It provides details about the trial phases, safety data expectations, and background on the drug and company. There is no financial data, regulatory filing references, shareholder information, or meeting materials. The document is an update on clinical development progress, which does not fit into financial or regulatory report categories. It is a general corporate announcement about clinical trial progress, best classified under Regulatory Filings (RNS) as a miscellaneous announcement that does not fit other specific categories.
2024-10-16 English
Becoming a substantial holder 18 pages 2.1MB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 filed under the Corporations Act 2001 Section 671B, titled 'Notice of initial substantial holder'. It details the substantial shareholding of JPMorgan Chase & Co. and its affiliates in IMMUTEP LTD, including voting power, relevant interests, associates, and transaction details. This form is a regulatory notification about changes in significant share ownership levels, specifically the initial substantial holder notice. It is not a financial report, earnings release, or management report. It fits the definition of a Major Shareholding Notification (MRQ). The document length is substantial and contains detailed shareholding data, confirming it is the actual notification, not just an announcement or certification. Therefore, the correct classification is MRQ with high confidence.
2024-10-16 English
Appendix 3Z - Anne Anderson 2 pages 110.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the cessation of a director and the director's interests in securities, with no securities held. This is a formal notification of a director's personal share transactions or interests, specifically a final notice upon ceasing to be a director. The content matches the definition of Director's Dealing filings, which report personal share transactions or interests of company directors and executives. The document length is short and focused solely on director interests, not financial results or management changes. Therefore, the correct classification is Director's Dealing (DIRS).
2024-10-13 English
2024 AGM & Key Dates 1 page 223.5KB
AGM Information Classification · 95% confidence The document is an ASX/Media Release announcing the date and key details for the upcoming 2024 Annual General Meeting (AGM) of Immutep Limited. It provides information about the AGM schedule, nomination deadlines, and mentions that the Notice of Meeting will be released later. The document does not contain the AGM materials or presentations themselves, nor does it include financial data or voting results. It is a notice about the AGM event rather than the AGM report or materials. Given the short length (1837 characters) and the nature of the content, this fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or announcements related to the AGM event.
2024-10-09 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.